WHO issues best practice advice for disease names
8 May 2015 | By Victoria White
WHO has called on scientists, national authorities and the media to follow best practices for disease names to minimise unnecessary negative effects...
List view / Grid view
8 May 2015 | By Victoria White
WHO has called on scientists, national authorities and the media to follow best practices for disease names to minimise unnecessary negative effects...
8 May 2015 | By
The FDA has lifted the clinical hold on clinical studies of ND0612H and ND0612L, NeuroDerm's product candidates for the treatment of Parkinson’s disease...
8 May 2015 | By Victoria White
The FDA has granted Fast Track Designation for cobiprostone, a locally acting chloride channel activator, for the prevention of oral mucositis.
8 May 2015 | By Victoria White
Eleven Biotherapeutics presented clinical data for EBI-005 for dry eye disease and allergic conjunctivitis at the ARVO 2015 Annual Meeting...
8 May 2015 | By Victoria White
The European Commission has approved Novartis’ Zykadia to treat adult patients with ALK+ NSCLC previously treated with crizotinib...
8 May 2015 | By Victoria White
The Asia-Pacific treatment market for psoriasis will almost double in value, from $690 million in 2014 to $1.2 billion by 2021, representing a CAGR of 8.4%...
7 May 2015 | By Victoria White
Ohr Pharmaceutical presented the results from the Phase II IMPACT study evaluating OHR-102 combination therapy for the treatment of the wet-AMD at ARVO...
7 May 2015 | By kdm communications
Operating capacity set to more than double in response to rising demand...
7 May 2015 | By Victoria White
The Bill & Melinda Gates Foundation are set to announce CHAMPS - a network of disease surveillance sites in developing countries...
7 May 2015 | By Victoria White
J&J has announced a first-of-its-kind partnership that enlists a third party to review compassionate use requests made for investigational medicines...
7 May 2015 | By Victoria White
Alexion Pharmaceuticals has announced that it is set to acquire Synageva BioPharma in a transaction valued at approximately $8.4 billion...
7 May 2015 | By Victoria White
The FDA has granted Breakthrough Therapy Designation for venetoclax for the treatment of people who have relapsed or refractory CLL with 17p deletion...
7 May 2015 | By
A 7-year study of a Nulojix regimen has demonstrated a significant relative risk reduction of death or transplant failure over a cyclosporine regimen...
7 May 2015 | By Victoria White
The global market for Alzheimer’s disease treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023...
6 May 2015 | By Victoria White
GSK, Telethon and OSR have submitted a marketing application to the EMA for a gene therapy to treat patients with a rare disease, ADA-SCID...